Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K4MH
|
|||
| Former ID |
DNAP001696
|
|||
| Drug Name |
Tapentadol hydrochloride
|
|||
| Synonyms |
Tapentadol; 175591-23-8; Nucynta; Palexia; UNII-H8A007M585; 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol; 3-((2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl)phenol; phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-; BN-200; H8A007M585; CG-5503; (R,R)-Tapentadol; Tapentadol [USAN:INN]; 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol; Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-; CG5503; BN 200; CG 5503; Tapentadol (USAN/INN); 3-(1-DIMETHYLAMINO-2-METHYL-PENTAN-3-YL)PHENOL
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute pain [ICD-11: MG31; ICD-10: R52.0; ICD-9: 338,780] | Approved | [1] | |
| Company |
Ortho-McNell Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C14H24ClNO
|
|||
| Canonical SMILES |
CCC(C1=CC(=CC=C1)O)C(C)CN(C)C.Cl
|
|||
| InChI |
1S/C14H23NO.ClH/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12;/h6-9,11,14,16H,5,10H2,1-4H3;1H/t11-,14+;/m0./s1
|
|||
| InChIKey |
ZELFLGGRLLOERW-YECZQDJWSA-N
|
|||
| CAS Number |
CAS 175591-09-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14892326, 24136893, 44936111, 47207665, 50598570, 57373488, 87692438, 124772162, 126644483, 126666948, 128445985, 135207317, 135693229, 135693230, 136980026, 137147726, 142418252, 144115428, 152090609, 160693267, 160865464, 162012004, 164041986, 172919383, 174527899, 175267498, 175427057, 179150074, 187051780, 210276624, 223519387, 223661873, 224282350, 226489097, 252481185
|
|||
| ADReCS Drug ID | BADD_D02115 ; BADD_D02116 | |||
| SuperDrug ATC ID |
N02AX06
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Modulator | [1] |
| Opioid receptor mu (MOP) | Target Info | Modulator | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Adrenaline and noradrenaline biosynthesis | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Monoamine Transport | ||||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.